Eczema drug dupilumab showed no extra psoriasis risk in a large study

If you use dupilumab for eczema, or your doctor has brought it up, here is reassuring news. It did not raise the chance of psoriasis. A large study of health records found that people on dupilumab were diagnosed with psoriasis no more often than people on steroid creams, other biologic drugs or JAK inhibitor pills.

Some doctors had reported psoriasis, a different skin disease with thick, scaly patches, in people who started the drug. That was a fair worry to raise. This study put it to the test head to head, and the worry did not hold up.

How the study worked

Researchers used two big health record networks, TriNetX and Epic Cosmos. They looked at people with atopic dermatitis, the most common form of eczema. The work was published in October 2026 in Experimental Dermatology. Records show diagnoses rather than skin exams, so the authors call for follow-up studies that add biopsies and genetic data.

What they found

In TriNetX, the team matched people who started dupilumab with similar people on other eczema treatments. Then they counted new psoriasis diagnoses over two years. The comparison groups were:

• Steroid creams
• Other biologics that work on the same part of the immune system (nemolizumab, lebrikizumab and tralokinumab)
• JAK inhibitor pills (abrocitinib and upadacitinib)

Against all three, dupilumab was not linked to more psoriasis. Against steroid creams, the comparison came out at 0.91 on the study’s scale, where 1 means no difference. Against the other biologics it was 1.03, and against JAK inhibitors it was 0.86. In plain words, the groups looked alike, and none showed extra psoriasis for dupilumab.

The second network, Epic Cosmos, has an even larger pool of patients. There the team compared individual drugs over a 17-month span. The results pointed the same way. Psoriasis was as common or less common with dupilumab than with the alternatives.

Two separate databases, built in different ways, landed in the same place. That makes the result easier to trust.

So why were cases reported?

Dupilumab calms one branch of the immune system, called Th2. One early idea was that this pushes the body toward another branch, Th17, which is tied to psoriasis. The new data do not support a risk that is specific to dupilumab.

The authors point to two other explanations. First, eczema and psoriasis can look alike, so a diagnosis can change as a rash develops. Second, some people carry a genetic tendency toward shifts in the immune system, whatever treatment they take. Both ideas still need confirmation in studies that follow patients over time.

What you can do today

You can keep your treatment plan with more confidence. Stopping a prescribed drug on your own is not needed, and it is not what this study suggests. Still, it is smart to keep an eye on your skin. Psoriasis tends to show up as thick, scaly, sharply edged plaques, which can look different from your usual eczema patches.

If a new patch like that appears, snap a photo with your phone so the date is saved with it. Then bring the photo to your next dermatology visit. A dated picture helps your doctor see how the patch has changed, and it takes less than a minute.